Practice management in the era of anti-VEGF therapy (Part I)

The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema